Report lays out blueprint for achieving Organon's purpose and
business imperatives to help women and girls achieve their promise
through better health
- Launch of Her Promise ESG platform creates a framework by
which the company will advance innovation and progress in women's
health and contribute to UN
Sustainable Development Goals
- Organon Her Promise Access Initiative set to prevent 120
million unintended pregnancies by 2030
KIRKLAND, QC, June 2, 2022 /CNW/ - Organon Canada Inc., an
affiliate of Organon (NYSE: OGN), a global women's healthcare
company, which employs over 120 people across Canada, today announced the publication of the
company inaugural Environmental, Social, and Governance (ESG)
Report for 2021. The ESG report introduces the company's ESG
platform, known as Her Promise, and details how the company is
working to help women and girls achieve the full potential of their
promise through better health. The publication of the ESG Report
and launch of Her Promise coincides with Organon's one year
anniversary and reflects the company's vision to create a better
and healthier every day for every woman in Canada and around the world, and to address
disparities by broadening access to treatments to the underserved.
The ESG Report was developed by Organon, Organon Canada Inc.'s
parent company, to disclose the company's priorities and areas of
As the only global women's healthcare company of its kind,
Organon is well positioned to help address several current and
growing women's health challenges. For example, nearly half of all
pregnancies worldwide – about 121 million in total – are
unintended, including in Canada.
According to a 2019 study, an estimated 218 million women and girls
(ages 15-49) in low-and-middle income countries had an unmet need
for modern contraception. In Canada, almost half of all pregnancies are
unplanned.i Through Her Promise, Organon is making
focused investments and forming strategic partnerships with the
goal of introducing and expanding access to health solutions to
help improve women's health and advance gender equity, inside and
outside Organon. Recently in Québec, Organon Canada worked
with the Quebec Ministry of Health and Social Services towards
giving women in the province access to more hormonal therapy
options to treat symptoms from menopause. This was a result of
women expressing their unmet medical needs earlier in the year in
that sphere of their life and the company listening to be part of a
"In just one year, Organon has made considerable progress in
addressing gender-related disparities in health by listening to
women and investing in areas where high unmet needs exist. Since
our launch, we have focused on treatment gaps that need to be
addressed, like unintended pregnancy, fertility and more, and will
continue to strive to deliver innovation, improve access and expand
choice for treatments areas that uniquely or disproportionately
affect women," says Kevin Ali,
Organon's Chief Executive Officer. "The goals stated in our first
ESG Report create a roadmap for the future of how we will continue
to propel forward and partner to transform the current women's
"Organon Canada will achieve
its purpose by supporting women's whole being, in addition to their
reproductive health, and through the delivery of medicines, like
biosimilars that treat diseases that impact women
disproportionally," says Michael
Casia, President and Managing Director, Organon Canada.
"Women present with and experience diseases differently than men,
and we are committed to helping address their unmet medical needs
today and into the future."
On its one-year anniversary, Organon is making the following
goals to achieve Her Promise:
- To improve access to low-cost contraceptives in 69 of
the world's least developed countries. Through the
Organon Her Promise Access Initiative, Organon is
working with global organizations to provide family planning
information, education and access to low-cost contraceptive
options. Organon's goal is to provide 100 million girls and women
in low- and middle- income countries with affordable access to
contraceptive options by 2030.
- To redefine and harness innovation in women's health.
Organon will dedicate a majority of its pre-clinical and clinical
development activity toward the unmet health needs of women.
Organon has already begun with development activities in high unmet
need areas including postpartum hemorrhage, endometriosis, and
- Expand access to treatment options that help improve her
health and help secure her promise. Working together with
global partners, Organon plans to expand treatment options
for post-partum hemorrhage in women, in both developed and
developing markets. We will also seek to help address affordability
of fertility treatments and access to education to decrease the
unmet medical need in fertility.
- Achieve balanced gender representation through all levels of
Organon globally by 2030 and pay equity. Organon has had a
strong start by launching with a Board of Directors that consists
of accomplished individuals with exceptional skills and expertise,
and also represents gender and racial diversity. Currently,
Organon's Board is the most diverse healthcare board on the S&P
500. At Organon Canada, 70 per cent of employees are women and 60
per cent of developmental opportunities, including promotions, were
provided to women since its launch as a company.
- Aim to support the transition to a low carbon economy, with
an ambition to achieve net zero greenhouse gas
emissions. We also aim to integrate water stewardship and
circular economy principles into our business models. The report
details concrete short- and mid-terms actions we will take to meet
these long-term ambitions.
- Uphold the highest levels of ethics and
integrity throughout its business.
In addition, as part of its commitment to advancing gender
equity through Her Promise, Organon has provided US $1.4M to Women Deliver to fund its Young Leaders
Program and other advocacy work, as well as support the Women
Deliver 2023 Conference (WD2023). The funding will help Young
Leaders across the world to achieve their advocacy goals in gender
equality and health through financial resources, mentorship, and
"The Board is committed to achieving both Organon's business
goals as well as contributing to societal goals, and to continuing
to drive the company's ESG strategy," says Carrie Cox, Board Chairman. "We are pleased to
be in a position to publish a comprehensive ESG report just one
year after the company's establishment and highlight our purpose
and goals in improving the health of women and girls.
The Board's governance committee, called the ESG Committee, is
comprised of five members and chaired by pharmaceutical
industry veteran Robert Essner, all
whom bring considerable expertise from across a variety of
For more details on Organon's ESG strategy, priorities, and
initiatives, download the full 2021 ESG Report here.
Organon is a global healthcare company with a focus on improving
the health of women throughout their lives. Organon has a portfolio
of more than 60 medicines and products across a range of
therapeutic areas. Led by the women's health portfolio coupled with
an expanding biosimilars business and stable franchise of
established medicines, Organon's products produce strong cash flows
that will support investments in innovation and future growth
opportunities in women's health. In addition, Organon is pursuing
opportunities to collaborate with biopharmaceutical innovators
looking to commercialize their products by leveraging its scale and
presence in fast growing international markets.
Organon has a global footprint with significant scale and
geographic reach, world-class commercial capabilities, and
approximately 9,300 employees with headquarters located in
Jersey City, New Jersey.
For more information, connect with us
on LinkedIn and Twitter.
Unintended pregnancy – Pregnancy Info, Accessed May 2022
SOURCE Organon Canada Inc.